|
Corona Remedies Limited proudly announces its successful accreditation with the Eurasian Economic Union – Good Manufacturing Practices (EAEU–GMP) certification, a significant milestone in the company’s global growth trajectory.
This certification paves the way for Corona’s entry into five EAEU member nations— Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan—under a B2B business model. It unlocks access to a pharmaceutical market estimated at USD 25 billion and aligns seamlessly with Corona’s long-term vision of fostering sustainable international partnerships.
EAEU–GMP certification further strengthens Corona’s focus across its four key therapeutic pillars—women’s health, cardio-diabetes, pain management, and urology.
Speaking of the occasion, Nirav K Mehta, CEO & managing director, Corona Remedies Limited said, “This recognition opens new avenues for Corona Remedies to contribute meaningfully to healthcare systems across the Eurasian region. More importantly, it reflects our core belief that quality healthcare should not be bound by geography. At Corona, we view this as a critical step in our journey to become a trusted international partner in pharmaceutical innovation. We remain deeply committed to advancing health outcomes through sustainable, scalable, and quality-driven solutions—because our responsibility extends far beyond compliance; it is rooted in care, trust, and the well-being of communities worldwide.”
Mehta further added “As one of the few pharmaceutical manufacturers in Gujarat to receive this prestigious certification, Corona underscores its operational excellence, rigorous quality systems, and adherence to global regulatory standards. With the guiding principle of “One World, One Quality” Corona continues its mission to deliver safe, effective, and trusted medicines—strengthening its footprint both in India and across the globe.”
Corona Remedies Limited is a domestic, branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other therapeutic areas. It is the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM) in terms of domestic sales.
|